Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases

A technology for pazopanib hydrochloride and pulmonary fibrosis, which is applied in the application field of pazopanib hydrochloride in the preparation of medicines for treating pulmonary fibrosis diseases, can solve problems such as the lack of pazopanib hydrochloride, and achieves good application prospects , No adverse reactions, the effect of slowing down pulmonary fibrosis

Inactive Publication Date: 2019-05-24
NANKAI UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no report that pazopanib hydrochloride can slow down pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases
  • Application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases
  • Application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0022] Example: Pazopanib hydrochloride reduces bleomycin-induced lung fibrosis in mice.

[0023] Animal model preparation: male C57BL / 6J, wild-type mice (8-10 weeks of age), with a mass volume concentration of 10% chloral hydrate and 0.5ml / 100g (body weight) given to mice by intraperitoneal injection anesthesia, traumatic in the trachea Inject 2U / Kg bleomycin.

specific Embodiment approach

[0024] The specific implementation is as follows: the mouse is anesthetized and recorded by weighing, the mouse is fixed on the operating table, the neck is disinfected with 70% alcohol, a scalpel is used to make a vertical wound about 1 cm in the neck of the mouse, and the mouse is separated with micro forceps Expose the trachea to the tissue, pierce the syringe into the trachea through the gap of the tracheal cartilage ring toward the heart, and then slowly inject a bleomycin physiological saline solution of a volume suitable for its body weight at a rate of 2U / kg, and immediately turn the animal upright and rotate it left and right to make The liquid medicine is evenly distributed in the lungs.

[0025] The blank control group was injected with the same volume of normal saline (0.9% Nacl).

[0026] Grouped administration: pazopanib hydrochloride treatment refers to the administration of 100 mg / kg pazopanib hydrochloride by gavage daily to mice on the 7-14 days of bleomycin treat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases, and further provides a medicine composition. The medicine composition contains the pazopanib hydrochloride, excipients and pharmaceutically acceptable salt, ester and hydrates of the pazopanib hydrochloride or compositions of the salt, the ester and the hydrates. The application and the medicine composition have the advantages that excellent effects can be realized by the pazopanib hydrochloride for pulmonary fibrosis, adverse reaction can be prevented, bleomycin-induced pulmonary fibrosis in mice can be relieved, and the medicine composition has an excellent application prospect for treating, relieving and improving the pulmonary fibrosis diseases.

Description

Technical field [0001] The invention relates to a new use of pazopanib hydrochloride, in particular to the application of pazopanib hydrochloride in preparing medicines for treating pulmonary fibrosis diseases. Background technique [0002] Pulmonary fibrosis (PF) is the end-stage clinical manifestation of many interstitial pulmonary diseases with different etiologies. It is characterized by persistent alveolar damage, fibroblast proliferation, and a large amount of extracellular matrix (ECM) deposition. A disease that causes varying degrees of inflammation and fibrosis in the alveoli and interstitium, which in turn leads to the destruction of lung structure and respiratory failure, so it is also called interstitial lung disease (ILD) or diffuse parenchymal lung disease (diffuse parenchymal lung disease, DPLD). [0003] Idiopathic pulmonary fibrosis (IPF) belongs to the idiopathic interstitial pneumonia (IIP) group in the family of interstitial lung diseases (ILDs). IPF is the mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61P11/00
Inventor 刘钦佚张德强龙士达吴舒扬王文瑞黄凯阮灏李霄鹤周红刚
Owner NANKAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products